Travel ConsultNurse Consult Reviewed
- Patient presented for a travel consultation regarding an upcoming two-week holiday to Southeast Asia.
- Countries and regions to be visited: Thailand (Bangkok, Chiang Mai), Vietnam (Hanoi, Ha Long Bay), Cambodia (Siem Reap).
- Duration of stay in each location: Thailand (7 days), Vietnam (5 days), Cambodia (2 days).
- Nature of travel: Leisure/tourism, with planned cultural excursions and some rural exploration.
---
Medical History
- Past medical history: No chronic conditions. History of seasonal allergies (pollen), well-controlled with over-the-counter antihistamines.
- Medications and herbal supplements: Loratadine 10mg daily as needed for allergies. No other chronic medications or herbal supplements.
- Allergies: Penicillin (rash), no known vaccine allergies.
---
Vaccinations
- Current vaccinations: Tetanus (last booster 5 years ago), Hepatitis B (full course completed), MMR (childhood), COVID-19 (completed primary course and one booster).
---
Vaccine Recommendations (based on local travel protocols and WHO guidelines):
- Recommended vaccinations for travel destinations: Hepatitis A, Typhoid, Japanese Encephalitis, and a Tetanus booster due to planned rural activities.
---
Malaria
- Malaria risk for areas: Low to negligible risk in major urban areas. Discussed potential for localized risk in some rural areas of Cambodia, particularly if trekking or staying overnight in less developed regions.
- Malaria medications discussed and associated information: Discussed atovaquone/proguanil 250mg/100mg, one tablet daily, starting 1-2 days before entering a risk area, during stay, and for 7 days after leaving. Patient advised on potential side effects (nausea, diarrhoea) and importance of compliance.
---
Yellow Fever
- Yellow fever vaccination risks, requirements and recommendations discussed at length. WHO Country List (latest update reviewed).
- Yellow Fever vaccine requirement or exemption for destination countries: Not required for Thailand, Vietnam, or Cambodia, as patient is not travelling from an endemic country. No specific exemption certificate needed.
- Vaccination risks including Yellow Fever-Associated Neurotropic Disease (YF-AND) and Viscerotropic Disease (YF-AVD) discussed, including increased age-related risk. NaTHNaC checklist completed with the patient.
---
Travel Advice
- Advice on safe food and water practices: Advised to drink only bottled or purified water, avoid ice in drinks, eat only well-cooked food, avoid raw fruits and vegetables unless peeled by the traveller, and be cautious with street food. Hand hygiene emphasised.
- Insect-borne precautions: Advised use of DEET-containing mosquito repellents (minimum 30%), wearing long sleeves and trousers at dawn and dusk, and sleeping under insecticide-treated mosquito nets if staying in rural or non-air-conditioned accommodation.
- Other relevant travel health advice: Discussed importance of comprehensive travel insurance, carrying a basic first aid kit (including bandages, antiseptic wipes, pain relievers, anti-diarrhoeal medication), sun protection, and safe sex practices. Advised caution regarding stray animals due to rabies risk.
---
Plan
- Vaccines recommended and administered or referred for: Hepatitis A (1st dose administered), Typhoid (administered), Japanese Encephalitis (1st dose administered), Tetanus booster (administered). Patient referred for 2nd dose of Japanese Encephalitis in 28 days.
- Prescribed medications for travel: Atovaquone/proguanil 250mg/100mg, 14 tablets, for malaria prophylaxis.
- Over-the-counter medications recommended: Loperamide, oral rehydration salts, paracetamol, and a broad-spectrum insect repellent.
- Travel insurance was advised: Strongly advised to obtain comprehensive travel insurance covering medical emergencies and repatriation.
- discussed mosquito avoidance, given advice on mosquito repellent, rabies prevention/management and malaria risk regions
- discussed other health advice and advised to seek medical care if needed
- patient was sent links for South African-based travel health resources (e.g. NICD, Department of Health) and shown where to monitor health alerts
---
Follow-Up
- Follow-up actions or appointments: Patient to return on 1 November 2024 for the second dose of Japanese Encephalitis vaccine.
---
Note:
Vaccines were administered by the practice nurse with thanks.
Patient remained for 15 minutes post-vaccination to monitor for immediate allergic reactions.
Travel ConsultNurse Consult Reviewed
- [describe reason for travel consultation, e.g. upcoming travel to a malaria-endemic area or Yellow Fever country]
- [list countries and regions to be visited, including cross-border travel e.g. Zimbabwe, Mozambique, Zambia, etc.]
- [mention duration of stay in each location]
- [mention nature of travel, e.g. business, family visit, safari, rural work, religious pilgrimage]
(Only include if explicitly mentioned in the transcript, contextual notes or clinical note, otherwise leave blank.)
---
Medical History
- [describe past medical history, including chronic conditions such as hypertension, diabetes, HIV, asthma, or history of TB]
- [mention medications and herbal supplements, including chronic meds from government pharmacy or private sector]
- [mention allergies, including to vaccines or antibiotics]
(Only include if explicitly mentioned.)
---
Vaccinations
- [list current vaccinations, e.g. Tetanus, Hepatitis B, BCG, MMR, COVID-19]
(Only include if explicitly mentioned.)
---
Vaccine Recommendations (based on local travel protocols and WHO guidelines):
- [mention recommended vaccinations for travel destinations, such as Hepatitis A, Typhoid, Yellow Fever]
(Only include if explicitly mentioned.)
---
Malaria
- [mention malaria risk for areas like Limpopo, Mpumalanga, KZN North Coast, or neighbouring countries]
- [mention malaria medications discussed and associated information, such as doxycycline or atovaquone/proguanil, including dosage and duration]
(Only include if explicitly mentioned.)
---
Yellow Fever
- Yellow fever vaccination risks, requirements and recommendations discussed at length. WHO Country List (latest update reviewed).
- [mention Yellow Fever vaccine requirement or exemption for destination countries]
- Vaccination risks including Yellow Fever-Associated Neurotropic Disease (YF-AND) and Viscerotropic Disease (YF-AVD) discussed, including increased age-related risk. NaTHNaC checklist completed with the patient.
(Only include if explicitly mentioned.)
---
Travel Advice
- [provide advice on safe food and water practices (e.g. bottled water, avoiding raw foods, safe street food habits)]
- [mention insect-borne precautions including use of mosquito repellents, long sleeves, insecticide-treated nets]
- [describe any other relevant travel health advice such as travel insurance, carrying a first aid kit, safe sex practices, heat exposure, or altitude risk]
(Only include if explicitly mentioned.)
---
Plan
- [vaccines recommended and administered or referred for]
- [list any prescribed medications for travel such as malaria prophylaxis or traveller’s diarrhoea treatment]
- [mention any over-the-counter medications recommended such as loperamide, electrolytes, or insect repellents]
- [mention whether travel insurance was advised]
- discussed mosquito avoidance, given advice on mosquito repellent, rabies prevention/management and malaria risk regions
- discussed other health advice and advised to seek medical care if needed
- patient was sent links for South African-based travel health resources (e.g. NICD, Department of Health) and shown where to monitor health alerts
(Only include if explicitly mentioned in transcript, contextual notes or clinical note, otherwise leave blank.)
---
Follow-Up
- [describe any follow-up actions or appointments e.g. return for second dose of vaccine, monitoring for side effects, or referral to travel health clinic]
(Only include if explicitly mentioned.)
---
Note:
Vaccines were administered by the practice nurse with thanks.
Patient remained for 15 minutes post-vaccination to monitor for immediate allergic reactions.
---
(Never come up with your own patient details, assessment, plan, interventions, evaluation, or plan for continuing care - use only the transcript, contextual notes, or clinical note as a reference for the information included in your note. If any information related to a placeholder has not been explicitly mentioned in the transcript, contextual notes, or clinical note, you must not state that it has not been mentioned and instead leave the relevant placeholder blank.)